10/587184

WO 2005/072770 PCT/US2005/001139

1/26 AP20 Rec'd PCT/PTO 25 JUL 2006

SEQUENCE LISTING

<110> FERRING B.V.

<120> NOVEL USE

<130> 052209-0113

<150> US 60/538,512
<151> 2004-01-26

<160> 43

<170> PatentIn version 3.2

<210> 1
<211> 34
<212> PRT
<213> Homo sapiens

<400> 1
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 2
<211> 34
<212> PRT
<213> Bos taurus

<400> 2
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 3
<211> 34
<212> PRT
<213> Homo sapiens

<400> 3
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
20 25 30

Thr Ala

<210> 4
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (23)..(23)
<223> 2-Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 4
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Xaa Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 5
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His
20 25 30

Asn Phe

<210> 6
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 6
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Glu Lys Lys Leu Glu Lys Val His
20 25 30

Asn Phe

<210> 7
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 7
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Leu Leu Arg Lys Leu Leu Gln Asp Leu His
20 25 30

Asn Phe

<210> 8
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Aib

<220>
<223> see specification as filed for preferred embodiments

<400> 8
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His Xaa Leu Ile Ala Glu Ile His
20 25 30

Thr Ala

<210> 9
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES

<222> (32)..(32)
<223> Thi

<220>
<223> see specification as filed for preferred embodiments

<400> 9
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Xaa
20 25 30

Thr Ala

<210> 10
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 10
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Leu Leu His
20 25 30

Thr Ala

<210> 11
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 11
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Phe Leu Leu His His Leu Leu Ala Glu Leu His
20 25 30

Thr Ala

<210> 12
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 12
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Glu Phe Leu Glu Lys Leu Ile Glu Lys Ile His
20 25 30

Thr Ala

<210> 13
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 13
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 14
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 14
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 15
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 15
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 16
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES

<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 16
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 17
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 17
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 18
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (16)..(16)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 18
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Xaa
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 19
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (20)..(20)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 19
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Xaa Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 20
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES

<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 20
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 21
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 21
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 22
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 22
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 23
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 23
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 24
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 24
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 25
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 25
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 26
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 26
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 27
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 27
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 28
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 28
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 29
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 29
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 30
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 30
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 31
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 31
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 32
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 32
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 33
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES

<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 33
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 34
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 34
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
20 25 30

His Asn Phe
35

<210> 35
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 35
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 36
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 36
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 37
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 37
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 38
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 38
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 39
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 39
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 40
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 40
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 41
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 41
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 42
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES

<222> (12)..(12)
<223> Aib

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (23)..(23)
<223> 2-Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 42
Ser Val Ser Glu Ile Gln Leu Xaa His Asn Leu Xaa Lys His Leu Asn
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 43
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib

<220>
<223> see specification as filed for preferred embodiments

<400> 43
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Xaa Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe